His decade-long tenure as head of the European Medicines Agency (EMA) may have ended, but Thomas Lönngren is already back in the regulatory saddle as a strategic advisor to NDA Group, an independent consulting group focused on reducing wasted drug development costs, ensuring new medicines get to market faster, and “improving the performance of the pharmaceutical industry”.
Lönngren left EMA at the end of last year (after granting an exclusive ‘exit interview’ with Pharmaceutical Executive), but his new role will again see him providing top level advice on strategic drug development related topics, including regulatory strategy and Health Technology Assessment, and working alongside fellow ex-regulators (NDA’s team comprises more than 25% ex-regulators from major EU Agencies, plus a specialist Advisory Board that consists of leading regulatory experts).
“I’ve recognized for a long time that the whole area of market access needs new ideas and a new vision,” said Lonngren of his new role. “I plan to further develop my ideas surrounding International Regulatory Strategies, coupled with pushing for a joined-up approach to HTA, to enable the best medicines to reach needy patients as efficiently as possible.”
NDA consults more than 400 drug development companies in the US and Europe, including 90% of the world’s top twenty pharmaceutical companies. It provides advice on drug development and helps companies to cut poor development candidates before costs escalate. Lonngren’s advisory board appointment is alongside other new specialists who will advise pharmaceutical companies how to best prove the value of their products to national agencies.